Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pique Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Many attempts to develop therapeutic cancer vaccines have focused on boosting immune system response to vanquish naturally immunogenic tumors. Pique Therapeutics is instead creating vaccines against non-immunogenic tumors, which since they don't stimulate the immune system, have never developed a way to evade it. Pique reasons that if those tumors can be made visible to the immune system, they will prove more susceptible to being overcome than tumors that are accustomed to fighting.

Related Content

A New Perspective on Cancer Immunotherapy
Start-Up Previews (6/07)
Start-Up Previews (6/07)


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts